Evofem Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $1.0M
- Price
- $0.00788
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.49%
- Volume
- 12.6K
About
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Quick stats
Shares outstanding132.5M
Computed float132.5M
Float / shares100.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001618835
Websitehttps://www.evofem.com
AI Summary
AI-generated1/5
minorbullishoperations update
Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global Growth Strategy
Evofem Biosciences contracted a second pharmaceutical manufacturer to produce PHEXX, its hormone-free on-demand contraceptive vaginal gel, to support global growth and supply chain flexibility.
Subject to FDA approval, the additional source is expected to reduce unit costs by 40% or more; the company plans to submit an sNDA in mid-2027 for product made at the new facility.
The milestone strengthens long-term product economics but carries execution and regulatory-timeline risk, and the release reiterates the company's limited cash resources and going-concern dependence on new capital.
Red flags
- cost benefits contingent on sNDA filing in mid-2027 and FDA approval -- multi-year timeline
- forward-looking statements disclose limited cash resources and going-concern reliance on new capital or business development transactions